^
    1d
    Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (clinicaltrials.gov)
    P1/2, N=54, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2026 --> May 2027
    Trial completion date • Checkpoint inhibition • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    PIK3CA mutation • PTEN mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Aliqopa (copanlisib) • ABP 206 (nivolumab biosimilar)
    1d
    QL1706 Plus Lenvatinib in Previously Treated Penile Cancer (clinicaltrials.gov)
    P2, N=47, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lenvima (lenvatinib) • Qibeian (iparomlimab/tuvonralimab)
    1d
    CLEAR-IT: Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, RenJi Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Lenvima (lenvatinib) • Kaitanni (cadonilimab)
    3d
    RESOLVE: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, University of Utah | Trial primary completion date: Apr 2026 --> Aug 2026
    Trial primary completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)
    3d
    Computational insights into the pH-dependent behavior of Ipilimumab-CTLA-4. (PubMed, Phys Chem Chem Phys)
    Decomposition analysis on binding energy further indicated that the overall antigen-binding mode was maintained, whereas the introduced charged residues modulated local interaction strengths. These results provide mechanistic insights into how targeted mutations modulate pH-dependent recognition, offering a framework for the rational design of safer therapeutic antibodies.
    Journal • IO biomarker
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Yervoy (ipilimumab)
    3d
    A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: May 2030 --> Aug 2030 | Initiation date: May 2026 --> Aug 2026 | Trial primary completion date: May 2026 --> Aug 2030
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1) • PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sirpiglenastat (DRP-104) • Hiltonol (poly-ICLC)
    3d
    Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant (clinicaltrials.gov)
    P2, N=8, Terminated, University of Cincinnati | N=30 --> 8 | Active, not recruiting --> Terminated; The study is closing due to low enrollment and feasibility of the study.
    Enrollment change • Trial termination
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    4d
    D798MC00002: Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors (2025-523947-36-00)
    P1/2, N=42, Not yet recruiting, AstraZeneca AB
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • volrustomig (MEDI5752)
    4d
    ADAPT-IT: A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    4d
    NIVIPI-Brain: Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (clinicaltrials.gov)
    P2, N=71, Active, not recruiting, Fundación GECP | Trial primary completion date: Mar 2026 --> Oct 2027 | Trial completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed
    4d
    IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=60 --> 20 | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    5d
    A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT (clinicaltrials.gov)
    P3, N=378, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • albumin-bound paclitaxel • Kaitanni (cadonilimab)